CA2229201A1 — Quinoline derivatives, their production and use
Assigned to Takeda Pharmaceutical Co Ltd · Expires 1997-04-24 · 29y expired
What this patent protects
The present quinoline derivatives of formula (I), wherein R1 is a group of formula (a) in which R5 is an aralkyl group, R6 is an alkyl group, X is an alkylene group, or an alkyl group which may optionally be substituted by halogen, R2 is an acylaminoaryl group, R3 is a halogenoar…
USPTO Abstract
The present quinoline derivatives of formula (I), wherein R1 is a group of formula (a) in which R5 is an aralkyl group, R6 is an alkyl group, X is an alkylene group, or an alkyl group which may optionally be substituted by halogen, R2 is an acylaminoaryl group, R3 is a halogenoaralkyl group, R4 is a carboxyl group which may optionally be esterified or amidated, or a salt thereof, have gronadotropin-releasing hormone antagonistic activity and are useful as propylactics or therapeutic agent for the prevention or treatment of several hormone dependent diseases.
Drugs covered by this patent
- Kalydeco (IVACAFTOR) · Vertex Pharms Inc
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.